


## KL001

<b>Cat. No.:</b>	HY-108468
<b>CAS No.:</b>	309928-48-1
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>22</sub> N <sub>2</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	398.48
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



### BIOLOGICAL ACTIVITY

<b>Description</b>	KL001 is a first-in-class cryptochrome (CRY, a flavoproteins that are sensitive to blue light, and is involved in the circadian rhythms of plants and animals) stabilizer which specifically interacts with CRY1 and CRY2. KL001 prevents ubiquitin-dependent degradation of CRY, resulting in lengthening of the circadian period. KL001 has the potential to control fasting hormone-induced gluconeogenesis <sup>[1][2][3]</sup> .
<b>In Vitro</b>	KL001 (0.03-71 μM) causes circadian period lengthening and amplitude reduction in a dose-dependent manner in stable U2OS reporter cell lines harboring Bmal1-dLuc or Per2-dLuc <sup>[1]</sup> . KL001 (2-8 μM; 18 h) represses glucagon-dependent induction of Pck1 and G6pc genes in a dose-dependent manner without affecting their basal expression in mouse primary hepatocytes <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Hirota T, et, al. Identification of small molecule activators of cryptochrome. *Science*. 2012 Aug 31;337(6098):1094-7.
- [2]. Kelleher FC, et, al. Circadian molecular clocks and cancer. *Cancer Lett*. 2014 Jan 1;342(1):9-18.
- [3]. Nangle S, et, al. Crystal structure of mammalian cryptochrome in complex with a small molecule competitor of its ubiquitin ligase. *Cell Res*. 2013 Dec;23(12):1417-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA